Hello – Nuclear power is shifting from a distant promise to an immediate growth story. U.S. energy plans call for tripling reactor capacity over the next 25 years, and major data-center operators are already reserving small modular reactors (SMRs)to secure reliable, low-cost, carbon-free power. To help investors get ahead of this accelerating trend, we’ve released an updated report: 7 Top Nuclear Stocks to Buy Now. Inside, you’ll learn about:
The only U.S. company licensed to produce next-gen HALEU fuel—a critical component for SMRs and advanced reactors The SMR developer already contracted for two gigawatt-scale data-center projects in Ohio and Pennsylvania An all-in-one ETF that bundles utilities, uranium miners, fuel suppliers, and breakthrough innovators into a single trade These seven names give you exposure to uranium mining, fuel enrichment, reactor construction and the steady cash flow of government contracts—all in one concise, easy-to-read guide. π Download your complimentary PDF now. No cost, no strings—just timely research before the mainstream spots the opportunity. Let’s get you ahead of the trend, Matthew Paulson
Founder & CEO, MarketBeat P.S. Regulations can slow nuclear projects, but early investors could ride this multi-decade tailwind for years. Grab the list now and decide which of these seven leaders earns a place in your portfolio.
This Month's Bonus Article
3 Dividend Kings That Earn Their Crown Every QuarterAuthor: Chris Markoch. Date Posted: 5/31/2026. 
Key Points
- Johnson & Johnson, PepsiCo, and Becton Dickinson have each raised dividends for more than 50 consecutive years.
- These Dividend Kings combine recession-resistant business models with long-term income growth and strong financial fundamentals.
- Investors seeking reliable dividend growth stocks may find attractive opportunities in healthcare and consumer staples leaders.
- Special Report: Elon’s “Hidden” Company
The Dividend Kings—companies that have raised their dividend for at least 50 consecutive years—represent one of the most exclusive clubs in investing. The entry requirement is a testament to financial discipline. A company must maintain uninterrupted dividend growth through recessions, market crashes, interest rate cycles, and industry disruption. Fewer than 60 U.S. companies hold the title as of 2026. But holding the title alone doesn't make a stock worth owning. Some Kings are slow-growth businesses propped up by yields that have risen primarily because the share price has fallen. The three below are different. Each carries the pedigree and the fundamentals to back it up. The Healthcare Dividend King With a Stronger Post-Spinoff Business
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the biggest story of his 26-year career - an economic shift not seen since 1776.
From the government taking stakes in Intel, Lithium Americas, and MP Materials, to sweeping political changes reshaping the economy, Stansberry argues a rare 'New 1776 Moment' is already underway. One Nobel Prize winner calls it a dividing line for all of society.
His presentation covers the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift. Watch Porter Stansberry's full briefing and learn how to prepare now
Johnson & Johnson (NYSE: JNJ) has increased its dividend for 64 consecutive years—a track record that stretches back to the early 1960s and has survived oil shocks, the dot-com crash, the financial crisis, and a global pandemic. But what makes JNJ particularly compelling today is how its business has changed. In 2023, J&J completed the spinoff of its consumer products division into a separate, publicly traded company called Kenvue (NYSE: KVUE), which houses brands such as Tylenol, Band-Aid, and Listerine. The move was controversial at the time, but the strategic logic has played out. The remaining J&J is now a pure-play pharmaceutical and MedTech company. That means the company now has a higher-margin business with a pipeline that management has backed with aggressive R&D investment. The legacy consumer division, while stable, was holding back the multiple. Without it, investors get direct exposure to J&J's oncology, immunology, and neuroscience pipelines. The stock is up approximately 50% over the past year, reflecting the market's belated recognition that the business is fundamentally better post-spinoff. The dividend yield sits around 2.3%, modest by Dividend King standards, but it is paired with a balance sheet that is one of only a handful in the S&P 500 to carry a AAA credit rating. For investors who want income growth backed by genuine business quality rather than financial engineering, J&J is the benchmark. The Consumer Staples Giant Built for Long-Term Income GrowthPepsiCo (NASDAQ: PEP) is one of those companies that perpetually underwhelms in bull markets and quietly outperforms over full market cycles. It has raised its dividend for 54 consecutive years and carries one of the most recognizable brand portfolios in the world, including Pepsi, Gatorade, Lay's, Doritos, Quaker, and Tropicana. More than 20 individual brands generate over $1 billion in annual sales each. The underappreciated part of the PepsiCo story is how that diversification functions as a hedge. When beverage volume softens, snack volumes hold up. When North American consumers tighten their spending, international growth picks up the slack. The company has demonstrated the ability to push through price increases without devastating volume, a form of real pricing power that not every packaged food company can claim. Organic revenue growth of 1% to 3% per quarter may not sound exciting, but it has remained remarkably consistent across economic environments while compounding meaningfully over the past decade. The dividend yield is currently around 3.9%, with a recent 4% dividend increase. That extends the company’s multi-decade track record of delivering above-inflation income growth. PepsiCo is not a stock that will make a portfolio double in two years. But it can quietly build wealth over a decade through dividends reinvested, earnings growth, and the kind of durability that makes it a reliable ballast when growth stocks are being repriced. For investors nearing or in retirement, or for anyone who wants income that genuinely grows in purchasing power, PEP belongs in the conversation. The Overlooked Medical Technology Dividend KingBecton, Dickinson and Co. (NYSE: BDX) is the Dividend King that isn’t a household name for most income investors. The company manufactures needles, syringes, infusion systems, diagnostic instruments, and lab automation equipment that hospitals and clinics continuously buy, regardless of the economic environment. That defensive revenue profile creates a firm foundation, but BDX also has a credible growth story layered on top. The company is investing heavily in its diagnostics and medication management businesses, both of which benefit from secular trends in hospital efficiency and infection control. Management has guided for low single-digit revenue growth in fiscal 2026 and earnings per share of $14.75 to $15.05 at the midpoint, representing modest but steady earnings growth. With a dividend yield of 2.8% that currently sits above the S&P 500 average, 53 years of uninterrupted dividend growth, and a business model that is genuinely recession-resistant, BDX offers something increasingly rare: income that doesn't come with meaningful existential business risk. It is the kind of holding that long-term investors look back on a decade later and wish they had bought more of at prices like these. |
No comments:
Post a Comment